Extraskeletal osteosarcoma: A European Musculoskeletal Oncology Society study on 266 patients.

A. Longhi, S. S. Bielack, Robert Grimer, J. Whelan, Reinhard Windhager, Andreas Leithner, A. Gronchi, David Biau, Paul C. Jutte, A. H. Krieg, F. M. Klenke, G. Grignani, D. M. Donati, R. Capanna, Jordi Casanova, C Gerrand, Gianni Bisogno, Stefanie Hecker-Nolting, M. Lisa, L. D'AmbrosioM. Willegger, Guido Scoccianti, S. Ferrari

Research output: Contribution to journalArticlepeer-review


PURPOSE: Prognosis of extraskeletal osteosarcoma (ESOS) is reported to be poorer than that of skeletal osteosarcoma. This multicenter retrospective study aimed to evaluate factors influencing ESOS prognosis. PATIENTS AND METHODS: Members of the European Musculoskeletal Oncology Society (EMSOS) submitted institutional data on patients with ESOS. RESULTS: Data from 274 patients treated from 1981 to 2014 were collected from 16 EMSOS centres; 266 patients were eligible. Fifty (18.7 had metastases at diagnosis. Of 216 patients with localised disease, 211 (98 underwent surgery (R0 = 70.6 R1 = 27. Five-year overall survival (OS) for all 266 patients was 47% (95% CI 40-54. Five-year OS for metastatic patients was 27% (95% CI 13-41. In the analysis restricted to the 211 localised patients who achieved complete remission after surgery 5-year OS was 51.4% (95% CI 44-59 and
Original languageUndefined/Unknown
Pages (from-to)9-16
Number of pages8
JournalEuropean Journal of Cancer
Publication statusPublished - Mar 1 2017


  • EMSOS, Extraskeletal osteosarcoma, Localised osteosarcoma

Cite this